News Archive

< Back to News & Events
February 28, 2024
Biotech’s top money raisers of 2023

Fierce Biotech

September 6, 2023
Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year

STAT

June 15, 2023
AI Drug Discovery Is a $50 Billion Opportunity for Big Pharma

Bloomberg Business

March 20, 2023
AAD 2023 – Takeda outdoes Bristol’s Sotyktu

Evaluate Vantage

March 18, 2023
Takeda’s $4 Billion Psoriasis Pill Helped Clear Skin in Mid-Stage Study

Bloomberg Business

February 8, 2023
Nimbus hopes to strike thrice

Evaluate Vantage

December 16, 2022
Nimbus CEO Jeb Keiper on negotiating a $4B deal and building an unorthodox biotech startup

BioPharma Dive

December 13, 2022
In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront

Endpoints

October 11, 2022
Sunny days for Nimbus: Lilly inks $496M biobucks deal for potential metabolic disease therapies

The Boston Globe

September 12, 2022
Nimbus Therapeutics raises $125m to test drug in psoriasis, lupus, and other diseases

The Boston Globe

September 12, 2022
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug

BioPharma Dive

September 12, 2022
Nimbus clinches $125M raise via big donor-backed private financing round following Bristol Myers’ TYK2 approval

Endpoints

August 16, 2022
Nimbus Therapeutics Automates CRO Data Ingestion to Accelerate Deployment to Scientists

Egnyte

June 8, 2020
BIO: Nimbus CEO: ‘We’re not just a one-hit wonder’

FierceBiotech

June 8, 2020
Nimbus picks 4 preclinical targets for the next chapter of its pioneering computational drug discovery work

Endpoints

July 25, 2019
Celgene turns to Nimbus on ‘highly prized’ I/O target — landing right in Bristol-Myers’ sweet spot

Endpoints News

June 10, 2019
Discovery of Allosteric Inhibition of Human ATP-Citrate Lyase

Cell Press: Trends in Pharmacological Sciences

April 4, 2019
Nimbus exposes complete ACLY structure, discovers allosteric inhibitory sites

BioCentury

March 20, 2019
Nimbus builds out scientific team with new heads of biology, preclinical development

FierceBiotech

February 14, 2019
Nimbus brings on Janssen discovery head as CSO with plans to expand its portfolio

FierceBiotech

July 18, 2018
Nimbus, Belcher, Khalil & More: Innovation at the Intersection Award Finalists

Xconomy

December 28, 2017
Can Innate Immune System Targets Turn Up the Heat on Cold Tumours?

Nature Reviews Drug Discovery

October 5, 2017
Nimble Move

BioCentury Innovations

October 3, 2017
Celgene joins the heavyweight partner club collaborating with Nimbus

Endpoints News

September 30, 2017
Don Nicholson of Nimbus: Making It Rain

Human Proof of Concept

September 26, 2017
The drug-maker’s guide to the galaxy

Nature

June 2, 2017
Gormley’s Take: Punching Back at Liver Cancer

WSJ Pro Venture Capital

April 5, 2017
Nimbus in full-on drug development partnership with Charles River

FierceBiotech

April 4, 2017
New England Venture Capital Association announces 2017 NEVY Awards nominees

Boston Business Journal

March 7, 2017
Gender tokenism and bias prevail in biotech boardrooms

Nature Biotech

February 17, 2017
Editorial: Targeted therapies for T-cell acute lymphoblastic leukaemia (T-ALL): what makes T-ALL TYK?

British Journal of Haematology

November 10, 2016
Cutting the cancer fat: A Nimbus-designed compound starves tumors of fatty acids

BioCentury Innovations

November 2, 2016
Nimbus Wins $200M Milestone Payment from Gilead toward ACC Inhibitor Program in NASH

Genetic Engineering & Biotechnology News

November 2, 2016
Gilead pays Nimbus $200M after fast progress in NASH

FierceBiotech

November 1, 2016
Gilead pays $200M milestone to Cambridge biotech Nimbus

Boston Business Journal

September 23, 2016
Stopping fat synthesis shrinks cancers, study finds

The San Diego Union-Tribune

May 13, 2016
Big Pharma Innovation in Small Places

Fortune

April 4, 2016
Gilead to buy Nimbus unit for up to $1.2b

The Boston Globe

April 4, 2016
Gilead paying up to $1.2B for Nimbus unit, drug candidate

Associated Press